Table 4.

Differences between those patients with and without previous exposure to an anti-tumor necrosis factor agent

Cytokine	Previous Exposure to Anti-TNF agent (20)	No Previous Exposure to Anti-TNF agent (27)	P value
ICAM [median in ng/mL (IQR)]	239.5 (207.6–322.8)	291.7 (239.5–311.2)	0.33
VCAM [median in ng/mL (IQR)]	552 (485.8–697.5)	452.9 (391-7–557.6)	0.04*
IL-8 [median in ng/mL (IQR)]	11.5 (7.7–35.1)	13.9 (9.2–26.8)	0.52
IL-1B [median in ng/mL (IQR)]	1.8 (0.7–3.0)	2.7 (1.1–3.9)	0.11
IL-6 [median in ng/mL (IQR)]	3.5 (2.8–6.2)	2.7 (1.9–4.1)	0.042*
TNF [median in ng/mL (IQR)]	10.6 (7.1–18.5)	8.7 (6.5–14.6)	0.47
C-reactive protein [median in mg/dL (IQR)]	2.1 (0.5–7.1)	1.2 (0.7–4.9)	0.14
Anti-TNF level [median in μg/mL (IQR)]	13 (10.6–19.4)	15.5 (10.6–19.8)	0.47
Hemoglobin [mean in gr/dL (SD)]	13.2 (12.4–14.1)	14 (13.4–15.7)	0.06
Age [mean in years (SD)]	43 (18)	36 (14)	0.17
Time on anti-TNF [median in months (IQR)]	12 (12–24)	16 (8.5–34.5)	0.24

^*statistically significant